


Summary of Extramural Support

Funding for the 2009-2010 academic year includes \$39,783,335 and \$4,340,992 in awards administered through the Office of Sponsored Programs and the South Alabama Medical Science Foundation, respectively.

Extramural Funds Totals for Recent Years

1997	\$14,981,699
1998	18,388,972
1999	19,108,225
2000	20,431,119
2001	20,723,188
2002	20,734,491
2003	23,244,111
2004	26,935,930
2005	40,065,869*
2006	31,904,662 **
2007	20,222,905
2008	20,818,609
2009	20,047,172
2010	44,124,327



*Includes 19.6 million dollar MCI construction grant

**Includes 12 million dollar MCI construction grant

**EXTRAMURAL FUNDING
(OCTOBER 1, 2009 – SEPTEMBER 30, 2010)**

BIOCHEMISTRY AND MOLECULAR BIOLOGY

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Sailen Barik	Amira	Amira Sponsored Research – Effects of a DP2 Receptor Antagonist on RSV-Induced Ocular Immunopathology	\$ 25,000
Donna Cioffi	NIH 4 R00 HL089361-03	Inactivation of Endothelial I _{src} Through Calcium-Phosphate Complexation	248,859
William Gerthoffer & Sailen Barik	NIH 1 R21 HL077726-06A1	Small Heat Shock Proteins in Smooth Muscle Plasticity	25,000
William Gerthoffer	NIH 1 R21 HL097220-01A1	Molecular Determinants of Smooth Muscle Phenotype in Pulmonary Hypertension	222,375
Sachin Gupte	NIH 5 R01 HL085352-04	Regulation of Vascular Smooth Muscle Calcium by NADPH Redox	367,500
Richard Honkanen	NIH 1 R21 NS0715553-01	Development of AHTS-Assay for Inhibitors of a Type 2C Protein Phosphatase IPPMD1/WIP1)	148,333
Petra Rocic	NIH 5 R01 HL093052-03	Regulation of Coronary Growth in the Metabolic Syndrome	362,552
Petra Rocic & Tracy Dodd	NIH 3 R01 HL093052-03S1	Regulation of Coronary Collateral Growth in the Metabolic Syndrome/Diversity Research Supplement	42,809

BIOCHEMISTRY AND MOLECULAR BIOLOGY (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Petra Rocic	NIH 3 R01 HL093052-02S1	Regulation of Coronary Collateral Growth in the Metabolic Syndrome	\$ 25,520
Total			\$ 1,776,136

BIOMEDICAL LIBRARY

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Robert Britton & Andrea Wright	NNLM 100200	Exhibition at the Alabama Rural Health Conference	\$ 1,266
Clista Clanton & Geneva Staggs	NNLM 100139	Promoting Clearer Communication Between Health Professionals and Patients	6,000
Justin Robertson & Beverly Rossini	NNLM 100137	Storm Warning: Hurricane Information, Planning, and Preparedness for Families	4,815
Beverly Rossini & Andrea Wright	NNLM 100262	University of South Alabama Biomedical Library Presents Harry Potter's World: Renaissance Science, Magic, and Medicine	2,000
Total			\$ 14,041

CENTER FOR STRATEGIC HEALTH INNOVATION (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Carl Taylor	HRSA 100374	Regional Response Planning 2011	\$ 86,737
Carl Taylor	HRSA 100376	Advanced Regional Response Training Center-Roadshow 2011 (ARRTC ROADSHOW 2011)	266,951
Carl Taylor	HRSA 100375	Advanced Regional Response Training Center-Basic 2011 (ARRTC BASIC 2011)	402,100
Carl Taylor	HRSA 100378	Advanced Regional Response Training Center-Advanced (AARTC ADVANCED 2011)	274,546
Total			\$ 11,602,987

COM ADMINISTRATION

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Samuel Strada & David Wood	NIH 1 C06 RR029870-01	Construction of a BSL-3 Laboratory of Infectious Diseases at the University of South Alabama	\$ 14,506,327
Samuel Strada	AHA 09PRE2260387-02	Advanced Cardiovascular Research for Medical Students	13,500
Total			\$ 14,519,827

COMPARATIVE MEDICINE

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Michele Schuler	NIH 5 K01 RR021971-05	Stem Cell Derivation in Two Neotropical Primate Species	\$ 122,850
Total			\$ 122,850

EMERGENCY MEDICINE

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
W. Scott McNair	Arete Therapeutics	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Exploratory, 28-Day Study to Examine the Effects of AR9281 on Blood Pressure and Glucose Tolerance in Patients with Mild to Moderate Hypertension and Impaired Glucose Tolerance	\$ 20,260
W. Scott McNair	Boehringer Ingelheim	A Randomized, Double-Blind, Double Dummy, Active Controlled, Parallel Group, Forced Titration Study to Compare the Fixed-Dosed Combination of Telmisartan 80mg plus Hydrochlorothiazide 25mg (T80/HCTZ25) Versus Telmisartan 80mg (T80) Monotherapy as First Line Therapy in Patients with Severe Hypertension	8,370
Frank Pettyjohn	Daiichi Sankyo	A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects with Hypertension	27,629

EMERGENCY MEDICINE (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Frank Pettyjohn	Novartis Pharmaceuticals	An 8-Week, Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Alikiren HCTZ vs Ramipril in Obese Patients (BMI>=30) with Stage 2 Hypertension	\$ 11,097
Frank Pettyjohn	Novartis Pharmaceuticals	An 8 Week, Randomized, Double-Blind, Parallel-Group, Multicenter, Active Controlled Study to Evaluate Anti-hypertensive Efficacy and Safety of Alikiren Administered in Combination with Valsartan versus Valsartan Alone in Patients with Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus	21,800
Frank Pettyjohn	Novartis Pharmaceuticals	A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study with a 24-Week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg Daily in Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on a DPP-4 Inhibitor (Sitagliptin) Alone or in Combination with Metformin	2,000
Total \$			91,156

FAMILY MEDICINE

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Carol Motley	HRSA 5 D56 HP05226-06-00	Pre-Doctoral Training in Primary Care	\$ 100,000
Allen Perkins	AFPRHB 090439	A Resident Curriculum in Rural Family Medicine	30,000
Allen Perkins	AFPRHB 090457	Student Preceptorship Subsidy	30,000
Allen Perkins	AFPRHB 100167	A Resident Curriculum in Rural Family Medicine	32,750
Total			\$ 192,750

INTERNAL MEDICINE

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Diego Alvarez	AHA 0835134N-03	Infusion of Resident Endothelial Progenitors Promotes Repair of Microvascular Barrier During Acute Lung Injury	\$ 77,000
Martha Arrieta	Housing Urban Development	Ross-Elderly Persons with Disabilities	8,370
Barney Beaver	Novartis Pharmaceuticals	A 104-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy of Alikiren on the Progression of Atherosclerosis in Patients with Coronary Artery Disease When Added to Optimal Background Therapy	22,426

INTERNAL MEDICINE (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Barbara Burckhardt	Roche	A Phase III, Double-Blind, Randomized Placebo-Controlled Study to Evaluate the Effects of RO4607381 on Cardiovascular (CV) Risk in Stable CHD Patients with a Documented Recent Acute Coronary Syndrome (ACS), Protocol No. NC20971	\$ 10,951
Errol Crook	NIH 5 P20 MD002314-04	Broad-Based Research Collaboratives on Minority Health	1,147,932
Michael Culpepper	Otsuka Maryland	A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Arm Trial to Determine Long-Term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease	37,556
Michael Culpepper	Amgen	EVOLVE – Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events	9,032
Michael Culpepper	Amgen	Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination with Low Dose Vitamin D for the Treatment of Subjects with Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis	12,720

INTERNAL MEDICINE (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Michael Culpepper	Dynavax	An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV to License Vaccine (Energix-B) among Adults (18-75 Years of Age) with Chronic Kidney Disease (CKD)	\$ 2,500
Michael Culpepper	Otsuka Pharmaceuticals	Multicenter, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimen in Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)	4,500
Jack DiPalma	Takeda Pharmaceuticals	Comparison of Lubiprostone and Placebo for Relief of Constipation from Constipating Medications	35,080
Karen Fagan	Actelion Pharmaceuticals	An Open-label, Multicenter Study Employing a Targeted 6-MWT Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of MRI on Cardiac Remodeling	18,469
Karen Fagan	Actelion Pharmaceuticals	A Phase IIIb, Multicenter, Open-Label of Patients with Pulmonary Arterial Hypertension Treated with Iloprost (Inhalation) Evaluating Safety and Inhalation Times When Converting from Power Disc-6 to Disc-15 with the I-Neb	5,044
Karen Fagan	Gilead Sciences	A Randomized, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension	2,500
Brian Fouty	AHA 09 GRNT2260917-02	Glucose 1 Transporter in Pulmonary Vascular Repair	82,500

INTERNAL MEDICINE (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Johnson Haynes	Novartis Pharmaceuticals	Incidence of Secondary Iron Overload in Adults with Sickle Cell Disease (SCD) Following Chronic, Intermittent Red Blood Cell (RBC) Transfusions	\$ 20,539
Johnson Haynes	Emmaus Medical	A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of L-Glutamine Therapy for Sickle Cell Anemia and Sickle B-Thalassemia	2,500
Jorge Herrera	Schering Plough	Long-term Follow-up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C	7,146
Jorge Herrera	Schering Plough	A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects with Chronic Hepatitis C Genotype 1 who Failed Prior Treatments with Peginterferon/Ribavirin	11,444
Jorge Herrera	Schering Plough	A Phase 3 Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1	33,368
Jorge Herrera	Schering Plough	A Phase 3 Safety and Efficacy Study of Boceprevir in Combination with Peginterferon α -2a and Ribavirin in Subjects with Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment with Peginterferon/Ribavirin	13,132

INTERNAL MEDICINE (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Jorge Herrera	Schering Plough	A Phase 3 Safety and Efficacy Study of Erythropoietin Use During Treatment of Subjects with Chronic Hepatitis C with Boceprevir, Peginterferon α -2b, and Ribavirin	\$ 31,423
Clara Massey	Bristol Myers-Squibb	A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalvular Atrial Fibrillation	31,533
Clara Massey	Novartis Pharmaceuticals	A Multicenter, Randomized, Double-Blind, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity, and Mortality in Patients with Chronic Heart Failure (NYHA Class II-IV)	5,549
Bassam Omar	Schering Plough	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome	58,800
Reynaldo Rodriguez	Braintree Laboratories	An Efficacy Evaluation of 2 Different Bowel Cleansing Preparation in Adult Subjects (Protocol BL1800-303)	3,600
Total			\$ 1,695,614

MICROBIOLOGY

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Jonathon Audia	NIH 3 R01 AI015035-32S1	Permeability of the Epidemic Typhus Rickettsia	\$ 355,059
Jonathon Audia	NIH 1 R56 AI085002-01A1	Elucidating the Role of Phospholipase in Induced Phagocytosis of the Epidemic Typhus Rickettsia	334,031
Paul Brett	NIH 1 R21 AI088418-01	Development and Testing of Novel Glanders Vaccine Candidates	210,089
Joseph Brewer	NIH 2 R01 GM061970-11A1	Homeostasis of the ER in Differentiating B Cells	319,185
Robert Lausch	Lion's Club	Lion's/USA Eye Research	40,000
David Wood	NIH 2 R56 AI020384-27	Genetic Analysis of Rickettsia Prowazekii	387,684
David Wood	NIH 3 R37 AI020384-26S1	Genetic Analysis of Rickettsia Prowazekii	129,955
		Total	\$ 1,776,003

MITCHELL CANCER INSTITUTE

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Thomas Butler	Genetech	An Observational Study of Treatment Pattern and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer	\$ 4,560

MITCHELL CANCER INSTITUTE (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Thomas Butler	Hoffman-LaRoche	An International Multicenter Open-Label 2-Arm Phase II Trial of Adjuvant Bevacizumab in Triple Negative Breast Cancer	\$ 43,099
Thomas Butler	Novartis Pharmaceuticals	A Phase II, Multicenter, Non-Randomized, Open-Label Study of TKI248 in Patients with Relapsed or Refractory Multiple Myeloma, who are with or without t(4;14) Translocation	3,000
Thomas Butler	Sarah Cannon Research Institute	A Randomized Trial of Ixempra vs. Taxol in Adjuvant Therapy Triple-Negative Breast Cancer (TITAN)	2,700
Donato Dumlao	Wyeth Research	Open-Label Extension Study to Assess the Safety of a Fixed Dose of Subcutaneous Methylnaltrexone in Subjects with Advanced Illness and Opioid-Induced Constipation	3,094
Michael Finan	Bristol-Myers Squibb	A Phase III Open-Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin	11,000
Hung Khong	Pfizer	A Phase III, Open-Label, Randomized, Comparative Study of Tiviclumab and Either Dacarbazine or Temozolomide in Patients with Advanced Melanoma	8,881
Hung Khong	Pfizer	A Phase 3 Study of SU011248 in Combination with Paclitaxel versus Bevacizumab with Paclitaxel in the First-Line Advanced Disease Setting in Patients Having Breast Cancer	13,485

MITCHELL CANCER INSTITUTE (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Hung Khong	Genta	GM307: A Multicenter, Randomized, Double-Blind Study of Dacarbazine with or without Genasene in Chemotherapy-Naïve Subjects with Advanced Melanoma and Low LDH	\$ 7,900
Hung Khong	Pfizer	A Randomized Phase 2b Study of Sunitinib Plus Oxaliplatin, 5-Fluorouracil and Leucovorin (FOLFOX) versus Bevacisumab Plus Folfox as First-Line Treatment in Patients with Metastatic Colorectal Cancer	12,363
Hung Khong	Wyeth Research	A Phase I/II, Open-Label Study of Neritinib (HKI-272) in Combination with Capecitabine in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or Locally Advanced Breast Cancer	14,674
Hung Khong	Novartis Pharmaceuticals	A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of ASA404 in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic Non-Small Cell Lung Cancer	13,550
Hung Khong	Novartis Pharmaceuticals	A Phase Ib, Open-Label, Two Arm Study of I.V. and Oral Panobinostat (LBH589) in Combination with I.V. Trastuzumab (Herceptin) and I.V. Paclitaxel as Treatment for Adult Female Patients with HER2 Overexpressing Metastatic Breast Cancer (MBC)	12,418
Hung Khong	Abraxis/Celgene	A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitadine (Vidaza) with the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients with Advanced or Metastatic Solid Tumors and Breast Cancer	44,580

MITCHELL CANCER INSTITUTE (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Hung Khong	Abraxis	ABX238-BC08US/A Phase I Study of Neoadjuvant Chemotherapy with Nanoparticle Albumin Bound Paclitaxel (Abraxane), Doxorubicin, and Cyclophosphamide (NAC) with or without Sorafenib in Patients with Stage I and II Breast Cancer	\$ 16,000
Hung Khong	Novartis Pharmaceuticals	A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First-Line Therapy in Women with HER2 Positive Locally Advanced or Metastatic Breast Cancer	6,456
Hung Khong	Astellas	A Phase II, Multicenter, Open-Label Study of YM155 plus Docetaxel in Subjects Stage III (Unresectable) or Stage IV Melanoma	28,641
Hung Khong	Astellas	A Phase II, Multicenter, Randomized Study of YM155 plus Docetaxel as First-Line Treatment in Subjects with HER2 Negative Metastatic Breast Cancer	6,500
Eddie Reed	Genetech	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of GDC-0449 as Maintenance Therapy in Patients with Ovarian Cancer in a Second or Third Complete Remission	6,461
Eddie Reed	Bristol-Myers Squibb	A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer	20,667

MITCHELL CANCER INSTITUTE (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
William Taylor	Novartis Pharmaceuticals	An Open-Label, Multicenter Phasee II Study to Compare the Efficacy and Safety of RAD001 as First-Line Followed by Second-Line Sunitinib	\$ 24,767
Total			\$ 304,796

NEUROLOGY

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Bassam Bassam	Novartis Pharmaceuticals	A 24-Month Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 0.5mg and 1.25mg Fingolimod (FTY720) Administered Orally Once Daily versus Placebo in Patients with Relapsing-Remitting Multiple Sclerosis	\$ 44,922
Ivan Lopez	Schwarz Biosciences	An Open-Label Extension Trial to Determine Safety and Efficacy of Long-Term Oral SPM 927 in Patients with Partial Seizures	17,809
Paul Maertens	Eisai Medical Research	A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures	2,383

NEUROLOGY (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Paul Maertens	Eisai Medical Research	An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Onset Seizures	\$ 6,545
Paul Maertens	Pfizer	A Placebo-Controlled, Rising Dose, Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pregabalin in Pediatric Patients with Partial Onset Seizures	11,088
Paul Maertens	Schwartz Biosciences	A Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Lacosamide (LCM) Oral Solution (Syrup) as Adjunctive Therapy in Children with Partial-Onset Seizures (Protocol SP847)	4,000
Paul Maertens	Schwartz Biosciences	A Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Lacosamide (LCM) Oral Solution (Syrup) as Adjunctive Therapy in Children with Partial-Onset Seizures (Protocol SP848)	3,700
Dean Naritoku	Schwartz Biosciences	An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Age 12-16 years old) with Epilepsy and in Adults (Age 18-55 years old) with Epilepsy	57,020

ORTHOPAEDIC SURGERY

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Valentina Grishko & Albert Pearsall, IV	Muscular Skeletal Transplant Foundation	Effect of Hyaluronic Acid on Chonrocyte Viability and Function During Cold Storage	\$ 100,000
Total			\$ 100,000

PEDIATRICS

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Karen Crissinger	Centocor, Inc.	A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients with Inflammatory Bowel Disease	\$ 28,112
Karen Crissinger	Johnson & Johnson PR&D	A Multicenter, Double-Blind, Parallel-Group, and Open- Label Long-Term Maintenance Study to Evaluate the Safety and Efficacy of Rabeprazole Sodium Delayed Release Pediatric Bead Formulation in 1 to 11 year-old Pediatric Subjects with Symptomatic and Erosive Gastro- Esophageal Reflux Disease	43,015
Benjamin Estrada & Mary Mancao	NIH N01 AI30025-01	A Phase 3, Randomized, Placebo-Controlled, Blinded Investigation of Oral Valganciclovir for Congenital CMV	19,400
Fabien Eyal	NIH A071868(M09A10144)	Gene Targets for IVH	1,483

PEDIATRICS (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Fabien Eyal	Biosynexus	A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight (VLBW) Neonates for the Prevention of Staphylococcal Sepsis	\$ 260,859
Hamayn Imran	NIH 111513010-7366495	Twitch Research Protocol	24,756
Hamayn Imran & Aarati Rao	Hyundai	Hope on Wheels Hyundai Pediatric Cancer Research Award	40,000
Mary Mancao & John Vande Waa	HRSA 5 H12HA23027-10-00	USA Family Specialty Clinic	332,356
Mary Mancao & John Vande Waa	ADPH RW- USAF-1011	USA Family Specialty Clinic Grant	112,118
Kenneth Rettig	ADPH C00113052	Endocrinology Clinic for State Newborn Screening Program	54,649
Lawrence Sindel	ADPH C00113051	Cystic Fibrosis Clinic for State Newborn Screening Program	40,440
Lawrence Sindel	C002-10/Center ID#101	Cystic Fibrosis Foundation Care Center	34,750
Felicia Wilson	NIH 98543-1234	Children's Oncology Group Grant	29,737
Felicia Wilson	NIH CA98543-08	Children's Oncology Group Grant	16,000

PEDIATRICS (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Felicia Wilson	ADPH C00113053	Comprehensive Sickle Cell Center for State Newborn Screening Program	\$ 40,440
Felicia Wilson	Novartis Pharmaceuticals	A Randomized, Multicenter, Open-Label, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and the Effects on Liver Iron Concentration of Repeated Doses of 10mg/kg/day of ICL670 Relative to Deferoxamine in Sickle Disease Patients with Transfusional Hemosiderosis	33,146
Total			\$ 1,111,261

PHARMACOLOGY

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
June Ayling	ACHE 100362	Protection by 5-Methyltetrahydrofolate (5MTHF) Against UV-Induced DNA Damage	\$ 25,000
Natalie Bauer	Gilead Sciences	Potential Role of Circulating Microparticles in Pulmonary Arterial Hypertension: Progression & Treatment Assessment	50,000
Natalie Bauer	Parker B Francis 100004	Pulmonary Microvascular Endothelial Response to Acute Hypoxia: Changes in RHOA/RHO Kinase Signaling	52,000
Judy Creighton	NIH 1 R01 HL102296-01	AMPK A1 and N-Cadherin Form A Functional Complex Essential for Lung Endothelial Barrier Repair	296,500

PHARMACOLOGY (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Mark Gillespie	AHA 09PRE2260451-02	Regulation of Hypoxic Gene Expression by G-Quadruplex Structures	\$ 21,770
Mark Gillespie & Glenn Wilson	NIH 5 R01 HL058234-10	DNA Lesions & Gene Expression	370,938
Mark Gillespie	NIH 5 P01 HL066299-09-10-PROJ2	Mitochondrial DNA Integrity and Endothelial Cell Free Radical Stress – Project 2**	300,049
Ivan McMurtry & Salina Gairhe	AHA 09PRE2250000-01	Endothelial Cell RHOA/RHO Kinase Signaling Regulates Vascular Smooth Muscle Cell Phenotype	21,770
Jack Olson	CMREF-05	Polyamines and Human Pulmonary Artery Hypertension	98,250
Thomas Rich	NIH 1 S10 RR027535-01	Request for Spectral Confocal Microscope	397,435
Thomas Rich	GSK 013767	Determination of the Influence of AKAPS on Localized cAMP Signal in Human Airway Smooth Muscle	57,960
Thomas Rich & Bing Zhu	NIH 5 R01 HL094455-02	cAMP Phosphodiesterase and Lung Endothelial Cell	428,020
Troy Stevens & Glenda Bonilla	AHA 10PRE4320054	Essential Role of Lactate Dehydrogenase A (LDHA) in Lung Neo-Angiogenesis	21,770

**Center for Lung Biology Program Project

PHARMACOLOGY (cont'd)

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Troy Stevens & Mark Gillespie	NIH 5 P01 HL06629	Program Project Grant Administrative Core 1**	\$ 199,348
Troy Stevens	NIH 5 P01 HL066299-09	Program Project Tissue Culture Core 2**	279,016
Troy Stevens	NIH 5 P01 HL066299-10 PROJ1	cAMP Endothelial Cell Permeability Permeability-Project 1**	356,524
Troy Stevens & Songwei Wu	NIH 2 RO1 HL060024-13	Store-Operated Calcium Entry: Lung Endothelial	370,938
Songwei Wu & Troy Stevens	NIH 5 P01 HL06299-10- PROJ3	Type-T Calcium Channels and Vond Willebrand Factor Release-Project 3**	275,326
		Total	\$ 3,622,614

**Center for Lung Biology Program Project

PHYSIOLOGY

<u>PRINCIPAL INVESTIGATOR</u>	<u>AGENCY</u>	<u>PROJECT TITLE</u>	<u>FISCAL YEAR FUNDING</u>
Stephen Ballard	Cystic Fibrosis Foundation	Mucociliary Clearance Consortium	\$ 108,000
Michael Cohen	Otuska Maryland Medicinal Labs	Evaluation of Cardioprotective Effect of Cangrelor in Cardiac Ischemia Reperfusion Injury Model in Cynomolgus Monkeys Using Open Chest Method	180,000
James Downey	NIH 5 R01 HL020648-30	Physical Factors and Coronary Flow	286,200
Thomas Lincoln	NIH 5 R01 HL066164-10	cGMP-Dependent Protein Kinase (PKG) Expression	330,750
James Parker	NIH 1 R01 HL092992-02 REV	TRPV4 Initiates Ventilator Induced Lung Injury	356,100
Mark Taylor	NIH 1 R01 HL085887-04	Coronary Artery Regulation by Small-Conductance Ca ²⁺ -Activated K ⁺ Channels	257,250
Mary Townsley	NIH 2 T32 HL076125-07	Training in Cell Signaling and Lung Pathobiology*	196,376
Mary Townsley	NIH 5 P01 HL06629906-10-PROJ4	TRPV4 in Regulation of Lung Endothelial Permeability Project 4**	280,141
Mary Townsley	GlaxoSmithKline	Research Collaboration Agreement-GSK-MPCEDD (TRPV4)	81,317
David Weber	NIH 5 R01 HL084159-03	Reactive Oxygen Species Regulation of Vascular Smooth Muscle Cell Migration	330,750
Total			\$ 2,406,884

*Center for Lung Biology Training Grant

**Center for Lung Biology Program Project

SURGERY	PRINCIPAL INVESTIGATOR	AGENCY	PROJECT TITLE	FISCAL YEAR FUNDING
	Patrick Bosarge	KCI USA	A Prospective Study Examining Clinical Outcomes Associated with the Management of the Open Abdomen with the ABTHERA Open Abdomen Negative Pressure Therapy System and Barker's Vacuum Packing Technique	\$ 9,677
	Richard Gonzalez & Glenn Cummings	DOT 281348-002	Enhancement of Global Positioning System Utilization in Emergency Medical Services	10,000
	Arnold Luterman	Mylan Pharmaceuticals	Prospective Evaluation of the Effects of Topical Therapy with Sulfamylon for 5% Topical Solution on Autograft Healing in Subjects with Thermal Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group	10,200
	Arnold Luterman	Stemnion	A Phase I/II Prospective Randomized, Double-Blind Safety and Dose-Determining Efficacy Clinical Trial Comparing ACCS (Amnion-Derived Cellular Cytokine Solution) in Three Different Regimens with Standardized Care Using 0.9% NaCL (Saline) Solution in the Topical Treatment of Partial-Thickness Burns	13,204
	William Richards	NIH 7 R01 D058197-09	Biomagnetic Signals of Intestinal Ischemia	215,239
	William Richards	SAGES	Downregulation of G6PD Activity is a Mechanism of Action Improvement of Type II Diabetes After Bariatric Surgery	30,000

SURGERY (cont'd)

PRINCIPAL INVESTIGATOR	AGENCY	PROJECT TITLE	FISCAL YEAR FUNDING
William Richards	American Society for Metabolic & Bariatric Surgery	Vascular Endothelium Changes After Bariatric Surgery	\$ 35,000
Paul Rider	Gore & Associates	Efficacy of Bioabsorbable Staple Line Reinforcement in Colorectal and Colo-anal Anastomoses	7,000
Paul Rider	DURECT Corp	Bupivacaine Effectiveness and Safety in SABER Trial (BESST)	9,500
		Total	\$ 339,820